Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

atment and prevention of recurrence of venous thromboembolism (VTE) in patients with deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and for the prevention of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation, respectively.1,2,8

Edoxaban is currently approved only in Japan, since April 2011, for the prevention of VTE after major orthopedic surgery, and was launched in July 2011 under the brand name Lixiana®. Elsewhere, including Europe and the US, edoxaban is currently in phase 3 clinical development and has not been approved in any indication.9 Results from the Hokusai-VTE clinical trial were presented at the European Society of Cardiology Congress on September 1, 2013 and published in the New England Journal of Medicine.8,9

About Daiichi Sankyo 

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.

Contact
Michaela Paudler-Debus, PhD
Daiichi Sankyo Europe
michaela.paudler-debus@daiichi-sankyo.eu 
+49 89 7808 685 (office)
+49 176 11780966 (mobile)

<
'/>"/>
SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 CVS Health (NYSE: CVS ) officially announced ... locations that sustained heavy fire damage during protests last week.  ... Baltimore over the past week or so, our hearts ... CVS Health President and CEO Larry Merlo . "Our purpose ... health. There is no better way that we can fulfill that ...
(Date:5/6/2015)... 2015  Rigrodsky & Long, P.A.: , Do you, ... AERI )? , Did you purchase your shares between ... you lose money in your investment in Aerie Pharmaceuticals, Inc.? ... Rigrodsky & Long, P.A. , including former Special Assistant ... complaint has been filed in the United States District Court for ...
(Date:5/6/2015)... Inc., a medical device company focused on the development ... disease, today announced Retired Congressman Norman Dicks ... in the company,s mission to treat vision impairment. ... Representative for Washington,s 6th congressional ... member of the Democratic Party. His district was located ...
Breaking Medicine Technology:CVS Health Announces it Will Rebuild Baltimore CVS/pharmacy Locations 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 2SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Aerie Pharmaceuticals, Inc. 3Retired Congressman Norman Dicks Joins LumiThera's Advisory Team 2
... Truphatek has successfully enticed one of the best known professionals in emergency ... , Dan White , formerly of AllMed ... new US subsidiary of Truphatek http://www.truphatek.com/ ... may be reached after this week at 573-240-0002 or by e-mail at ...
... Oct. 6 AMICAS, Inc. (Nasdaq: AMCS ), ... launch AMICAS RIS(TM) Version 5.5 at RBMA,s 2009 Fall ... 13. AMICAS will be in booth #203. , (Logo: ... RIS Version 5.5 introduces sophisticated workflow tools to help ...
Cached Medicine Technology:New Places and People - Truphatek opens USA subsidiary 2New Places and People - Truphatek opens USA subsidiary 3AMICAS Launches Major New Version of Radiology Information System at RBMA 2009 2AMICAS Launches Major New Version of Radiology Information System at RBMA 2009 3
(Date:5/6/2015)... 06, 2015 The Beryl Institute announces ... of Patient Experience Journal (PXJ), an international, open access, ... understanding and improving patient experience. The second volume of ... conversation globally, helps align the voices engaged and provides ... Published in association with The Beryl Institute, Volume 2, ...
(Date:5/6/2015)... Is Colorado’s legal cannabis industry the victim ... State will mark the 18-month milestone of its historic ... while Colorado’s legal marijuana industry has been successful and ... facing some new challenges. , For example, many marijuana ... in the wake of last month’s “420” cannabis celebrations. ...
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 vcfo, ... finance, HR, IT and operational support to optimize business ... Consulting CFOs, Jack Lynch and Michael Scheaffer. Both Lynch ... finance and leadership experience. , “We are delighted ... Ellen Wood, vcfo CEO. “Leveraging their background in financial ...
(Date:5/6/2015)... 2015 Anitoa Systems, (“Anitoa”), a Palo ... University of China, has successfully demonstrated a handheld real ... sensor. Anitoa’s handheld qPCR is shown to be ... RNA’s, including hepatitis B, C, and E. Coli. This ... per sample and over 9 orders of magnitude dynamic ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and importer, Our ... having one the best Extra Virgin Olive Oils in the ... of Greece and known as Laconiko , received the ... Olive Oil, which is defined by the competition as “the ... producer applicants from 25 different countries applying, Laconiko stood out ...
Breaking Medicine News(10 mins):Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2
... BALTIMORE, April 8, 2008 The Johns Hopkins ... agreement with the,University of Patras, the third largest ... student and faculty exchanges., The two schools ... 2008, when representatives from the 43-year-old Greek public,institution ...
... - Sentara Heart Hospital and Sentara Virginia ... Beach General Hospital will use SPY routinely, ... a developer of real-time medical imaging and image guidance,systems ... in Norfolk, Virginia and Sentara Virginia Beach General,Hospital in ...
... PHOENIX, April 8, 2008 NutraCea (OTC Bulletin,Board: NTRZ), ... and technology, announced today that they have accelerated their,plans ... Pelotas,Brazil to meet the demand for rice bran oil ... the plant was operating at less than,one third of ...
... in waking up since coffee, SPARTA, N.J., April 8, ... feeling refreshed and ready to go, you,re not alone. Morning,grogginess ... even driving ability. Fortunately, a unique and ingenious,solution has come ... before,bedtime that will help you to wake up in the ...
... Company acts to ,ensure the integrity of this critical step ... ... April 8, 2008 Navigenics, a,personalized genetic health services company, ... for consumer genomic testing services,and that it will seek broad, ...
... ... Month, PRINCETON, N.J., April 8, 2008 ... regarding the poor state of sexual health in America and urging,Americans to petition ... Evolve tour is designed to address this head on by,inspiring a positive sexual ...
Cached Medicine News:Health News:Johns Hopkins Medical School Sets Research and Teaching Collaboration with University of Patras in Greece 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 3Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 4Health News:Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule 2Health News:Demand for NutraCea Rice Bran Oil Prompts Major Expansion of Irgovel Plant Ahead of Schedule 3Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers 2Health News:Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers 3Health News:Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers 4Health News:Navigenics Proposes Standards for Personal Genomics Services, Coupled With Prospective Outcomes Studies, to Safeguard Consumers 5Health News:Video: Rubber Hits the Road as Trojan(R) Campaigns for Sexual Health in America to Evolve 2Health News:Video: Rubber Hits the Road as Trojan(R) Campaigns for Sexual Health in America to Evolve 3
Cementless hip system...
... knee system continues the "Consensus Concept" ... engineering with the diversified experience of ... is an affordable knee system that ... are designed to provide both joint ...
... System offers a femoral option and tibial ... action that engages at 60 degrees of ... roll-back motion and allow for 130 degrees ... conjunction with the femur is designed to ...
... The P.F.C. SIGMA Total Knee System is ... solutions for a variety of clinical indications. ... Knee System introduced in 1984, P.F.C. SIGMA ... clinical proof.,P.F.C. SIGMA is designed to address ...
Medicine Products: